A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Phase of Trial: Phase III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Roxadustat (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ROCKIES
- Sponsors AstraZeneca
- 08 Nov 2019 Results published in the Media Release
- 07 Nov 2019 Results presented in an AstraZeneca media release.
- 30 Oct 2019 According to an AstraZeneca media release, pooled efficacy and cardiovascular safety analyses data from the phase III OLYMPUS and ROCKIES trials will be present in oral presentations at the American Society of Nephrology (ASN) Kidney Week 2019, which takes place from 5-10 November 2019 in Washington, DC, US.